In order to review the clinical course, laboratory findings, and outcome of children with vertically acquired HIV infection and Pneumocystis carinii pneumonia, questionnaires were sent to paediatricians in the British Isles who had reported P caninii pneumonia and HIV infection through the British Paediatric Surveillance Unit (BPSU). Paediatric reports from the BPSU are linked to reports of pregnancies in HIV positive women and laboratory reports. P caninii pneumonia was the most frequently reported AIDS indicator disease at AIDS diagnosis, occurring in 22/56 (40%) children born in the British Isles; in a further two children P carinii pneumonia occurred after another AIDS indicator disease. The median age at P carinii pneumonia diagnosis was 4-1 (1-4-27-3) months and in 48% it occurred with other AIDS indicator diseases. Despite intensive treatment the three month survival was only 38%. The nine children surviving P carinii pneumonia subsequently developed further AIDS indicator diseases, in particular HIV encephalopathy and four have since died. P carinii pneumonia was present at AIDS diagnosis in 65% of children developing AIDS in the first year of life and caused 82% of infant deaths. Most children were not known to be at risk of HIV until they presented with P carinii pneumonia. 
In order to review the clinical course, laboratory findings, and outcome of children with vertically acquired HIV infection and Pneumocystis carinii pneumonia, questionnaires were sent to paediatricians in the British Isles who had reported P caninii pneumonia and HIV infection through the British Paediatric Surveillance Unit (BPSU). Paediatric reports from the BPSU are linked to reports of pregnancies in HIV positive women and laboratory reports. P caninii pneumonia was the most frequently reported AIDS indicator disease at AIDS diagnosis, occurring in 22/56 (40%) children born in the British Isles; in a further two children P carinii pneumonia occurred after another AIDS indicator disease. The median age at P carinii pneumonia diagnosis was 4-1 (1-4-27-3) months and in 48% it occurred with other AIDS indicator diseases. Despite intensive treatment the three month survival was only 38%. The nine children surviving P carinii pneumonia subsequently developed further AIDS indicator diseases, in particular HIV encephalopathy and four have since died. P carinii pneumonia was present at AIDS diagnosis in 65% of children developing AIDS in the first year of life and caused 82% of infant deaths. Most children were not known to be at risk of HIV until they presented with P carinii pneumonia. are followed up annually to monitor clinical progression, age at onset of AIDS, and age at death. Paediatricians are requested to report if a child develops AIDS or dies in the interim.
Further details on the clinical illness in children reported with P carinii pneumonia were sought from the paediatricians using a standard questionnaire, maintaining confidentiality. Data were collected on the presenting illness, method of diagnosis, treatment, use of ventilation, and outcome of the illness. These data were combined with data collected through the surveillance scheme. Median (range) age at P carini
Interval between onset of symptoms and starting treatment (days) 13 (3-49) 11* (2-42) 11 No (%) with P carinii pneumonia diagnosis: Presumptive Twenty seven children were initially reported to have P carinni pneumonia. However, after questionnaires on the clinical details were returned, the diagnosis had been revised in three children. In two of these children, a confirmed diagnosis of cytomegalovirus and adenoviral pneumonia respectively had been made, and in the third, it was not possible to obtain any information about the diagnosis, but the child is alive and well, with a high CD4 count at age 5 years.
Among the 55 children with AIDS born in the British Isles, P carinii pneumonia was observed only in infancy and occurred in 22 (40o/%) at AIDS diagnosis; among the 27 born abroad, only two (70/o) had P carinii pneumonia at AIDS diagnosis and both were over a year of age (fig 1) . Two children born in the British Isles developed P carinni pneumonia after an earlier AIDS defining illness (table 1) .
Of the 24 children with P carinii pneumonia, who were born in the British Isles, a definitive diagnosis was made in 18 (75%), based on the demonstration of pneumocystis with either silver stain or immunofluorescence with monoclonal antibodies (table 2); in six (25%), the diagnosis was made on clinical and radiological grounds.
In 11 children, P carinii pneumonia was the sole indicator disease at the time the child fulfilled the paediatric AIDS definition, and in 11 it occurred with other indicator diseases (table 1). These included severe failure to thrive (n= 6), cytomegalovirus (n= 3), severe failure to thrive and cytomegalovirus (n=l), and severe failure to thrive with encephalopathy (n= 1). In three children, both cytomegalovirus and P carinii pneumonia were isolated from bronchial secretions, and in one cytomegalovirus was isolated with P carinni pneumonia from lung tissue at postmortem examination. Only three children, all under 4 months of age, had no manifestations of HIV infection at or before P carinii pneumonia diagnosis. In the remainder other manifestations included failure to thrive (not meeting the AIDS definition), oral candida, bacterial infections, hepatosplenomegaly, and thrombocytopenia.
T cell subsets were measured within a month (before or after) of P carinii pneumonia diagnosis in 15 children, and in all but two were less than 1500/mm3, the level below which P car-inii pneumonia prophylaxis is recommended in infants.6 However, of the eight children known to have HIV before P carinii pneumonia diagnosis, only four had CD4 counts measured before the P car-inii pneumonia illness and in two these were below the threshold for prophylaxis. Time after AIDS diagnosis (months) Figure 2 Survival of children born in the British Isles afterfirst AIDS indicator disease in the first year of life; solid line indicates P carinii pneumonia as first AIDS indicator disease (n=22) and dotted line otherfirst AIDS indicator diseases (n= 12). (The first AIDS diagnoses in these 12 children were severe failure to thrive, lymphocytic interstitial pneumonitis, severe recurrent bacterial infections, HIV encephalopathy, and cytomegalovirus.) P carinii pneumonia subsequently developed further AIDS indicator diseases, in particular HIV encephalopathy which developed in seven (78%) (table 3). Figure 2 compares survival of children after P carinii pneumonia with that of children developing other AIDS indicator diseases in the first year of life. Of the 34 children developing AIDS in infancy, 22 (65%) had P carinii pneumonia as the first AIDS indicator disease, occurring either alone or in combination. Of the 12 children who developed other AIDS indicator diseases, two subsequently developed P carinii pneumonia from which one child died. Among the children who presented with P carinii pneumonia as their first AIDS indicator disease and who survived the first three months, the subsequent survival pattern was similar to those who first developed other AIDS diagnoses. P carinii pneumonia accounted for 14/17 (82%) deaths occurring in the first year of life among children with vertically acquired HIV infection born in the British Isles.
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Discussion
The spectrum of AIDS and clinical pattern of P carinii pneumonia in children with vertically acquired HIV infection in the British Isles is similar to that reported elsewhere. [1] [2] [3] [4] 7 8 Findings are similar to those in USA where 390/o of children with AIDS presented with P carinii pneumonia which was the most common AIDS indicator disease.6 As in other studies,3 4 9 the outcome was poor despite availability of intensive care support and the use of specific antimicrobial treatment and steroids. All children in our series were young and two developed symptoms under 6 weeks of age. The poor prognosis may be explained, in part, by the fact that P carinii pneumonia is likely to be a primary infection in young infants rather than a reactivation disease, and may be particularly severe in the presence of a damaged or immature immune system and immature lungs. In children with other congenital immunodeficiencies P carinii pneumonia also occurs most often in infancy.10
In a third of children in this series, P carinii pneumonia was associated with severe failure to thrive. It is difficult to determine whether severe failure to thrive was secondary to P carinii pneumonia itself, or whether it was due to other HIV related manifestations, such as undiagnosed HIV encephalopathy or gastrointestinal problems. Cytomegalovirus infection was reported as a coincident AIDS indicator disease in four children with definitive P carinii pneumonia, based on finding cytomegalovirus in bronchial secretions. However, as cytomegalovirus is frequently cultured from asymptomatic HIV infected children, demonstration of cytomegalovirus infected cells in histological specimens is often considered necessary to diagnosis cytomegalovirus infection. Indeed, Glaser et al observed no difference in outcome or survival from P carinii pneumonia in children when cytomegalovirus was isolated from bronchoalveolar lavage fluid or lung biopsy specimens and not specifically treated."I The association between P carinii pneumonia and subsequent HIV encephalopathy, which was reported in 78% of children surviving P caninii pneumonia in this series, has also been observed by others.' All children in this study were treated with high dose TMP-SMX and five (all white) developed adverse reactions. Van Altogether 79% of the children with P carinii pneumonia who required ventilation died, a figure similar to the 84% mortality reported by Vernon et al. 4 The numbers in both series are small, making it difficult to identify clinical features which might characterise those children with a better chance of surviving and who might benefit from ventilation. Children were ventilated for as long as 34 days before death, and in addition to the poor outcome, this raises the question as to whether it is appropriate to ventilate children with severe P carinii pneumonia and HIV at a very young age.
In this series, children had symptoms for a median of 11 days before the diagnosis of P carinii pneumonia or initiation of treatment. There is a need for increased awareness of P carinii pneumonia in young infants so that early treatment, which in adults with HIV infection and P carinii pneumonia has been shown to improve survival, can be initiated.
The predictive value of the CD4 count, upon which recommendations for prophylaxis are based6 is problematic. P carinii pneumonia has been described in a 19 day old infant with HIV infection'3 and even with frequent CD4 count measurements from birth, children at risk of P carinii pneumonia may not qualify to receive prophylaxis. In this series only two of the four children who had CD4 counts measured before P carinii pneumonia had CD4 counts below the threshold recommended for prophylaxis,6 and this has been reported by others.9 14 Where facilities for early diagnosis of HIV are available, it may be appropriate to give TMP-SMX early to all HIV infected children, with the additional advantage of helping to prevent bacterial infections.'5 If early diagnosis of HIV infection or frequent follow up of the child are not possible, it may be preferable to offer P carinii pneumonia prophylaxis to all children born to HIV positive mothers until HIV infection status is clarified, '6 while recognising that many children would receive TMP-SMX unnecessarily, with the accompanying possibility of haematological or allergic toxicity. At present the uncertainty in this area is reflected in clinical practice. In this series, only one of eight children developing P carinii pneumonia and known to be at risk had received prophylaxis. In the British Isles, of the 218 children followed up prospectively from birth, only 13 had been reported to have received prophylaxis; three of these had definitive HIV infection, two are now uninfected, and eight are of indeterminate infection status. However, some centres in the British Isles are now giving prophylaxis at 2-3 weeks of age to all children born to HIV positive women until the child is shown to be uninfected (personal communication). The risks and benefits of this and other strategies for P carinii pneumonia prophylaxis require further study.
Whatever policy for primary prophylaxis is implemented, children at risk of developing P carinii pneumonia require identification and intensive follow up from birth. In London, only 17% of babies born to positive women are recognised before delivery.5 Along with advice about the risks of transmitting HIV through breast feeding, prevention of P carinii pneumonia is another compelling incentive for offering HIV screening in pregnancy. 
